Researchers work to improve outcomes of lymphoma patients
Researchers at the University of Nebraska Medical Center (home of the Fred Pamela Buffett Cancer Center) have discovered that patients with diffuse large B-cell lymphoma don’t respond well to the standard drug therapy used to treat this type of cancer if they have high levels of a gene called STAT3. The findings are published in the November issue of the Journal of Clinical Oncology, the medical journal of the American Society for Clinical Oncology.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.